What is MS Phase 3 Study DECIDE?

Category: Others


See also: Clinical Trial

DECIDE is a Phase III, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis.

No patients have reported taking MS Phase 3 Study DECIDE.
Last updated:
There are no evaluations for MS Phase 3 Study DECIDE.